ACTIVApatch Comparison: 4-Hour vs. 12-Hour Treatment

IontoGo 4.0 vs. 12.0: Which ACTIVApatch Treatment Time Fits?

ACTIVApatch IontoGo 4.0 and IontoGo 12.0 are self-powered, single-use iontophoresis patches built around the same basic treatment concept: each is designed to deliver an 80 mA-min electrical iontophoresis treatment without an external dose controller, lead wires, or separate saline preparation.

The difference is time.

IontoGo 4.0 delivers its labeled treatment over approximately four hours. IontoGo 12.0 spreads the same labeled electrical dose over approximately 12 hours.

That makes the choice primarily about treatment time and current delivery profile, not about one patch holding more medication, having a larger treatment area, or delivering a larger electrical dose. Current manufacturer specifications list the same 2.0 cc reservoir capacity and 11.4 cm² active area for both models.

IontoGo 4.0 vs. IontoGo 12.0 at a glance

The biggest difference is not dose—it is how long delivery takes

Both IontoGo models have the same labeled 80 mA-min electrical treatment.

IontoGo 4.0 reaches that treatment capacity over approximately four hours. IontoGo 12.0 uses approximately three times as long.

That means the 4.0 uses a higher overall current-delivery profile over a shorter period, while the 12.0 distributes treatment over a lower-current, longer-duration profile. It does not mean that IontoGo 4.0 contains “stronger medication" or that IontoGo 12.0 provides a smaller medication dose.

Electrical dose and medication dose are not interchangeable measurements. We explain this distinction in detail in SHUNT Technology in ACTIVApatch.

When the 4-hour format may fit the workflow better

IontoGo 4.0 is designed around a shorter treatment window.

The 4-hour format suits workflows that require treatments within a specific timeframe, avoid impractical twelve-hour adhesive wear, or minimize disturbance to the application site.

The manufacturer's IFU specifically notes that excessive motion at the application site can reduce electrode-to-skin contact, potentially create uneven current distribution, and increase the risk of irritation. This information makes the actual location and the patient's activities during the prescribed wear period relevant to model selection.

The reason to choose IontoGo 4.0 should therefore be stated as follows:

The prescribed 80 mA-min treatment needs to be completed using the IontoGo four-hour delivery profile.

It should not be advertised as universally “stronger,” “more effective” or better for a particular diagnosis.

When the 12-hour format may fit better

IontoGo 12.0 is the extended-wear version.

It spreads the labeled 80 mA-min electrical treatment over approximately 12 hours rather than four, providing a different current-time profile while retaining the same 2.0 cc reservoir capacity and 11.4 cm² active area.

That can be useful when a clinician specifically chooses an extended delivery profile and the patient can reliably maintain appropriate patch contact for the longer prescribed period.

The 12-hour format should not, however, be marketed as automatically better for sensitive skin.

Both IontoGo IFUs warn that iontophoresis can cause irritation or burns. Longer wear means longer adhesive contact with the skin, while the shorter-wear model delivers the electrical treatment over less time. Those competing factors mean there is no responsible universal rule that “12 hours = safer for sensitive skin.”

Shorter current delivery vs. longer adhesive wear

This is the practical tradeoff that deserves more attention than generic “quick versus gentle” language.

Can I remove IontoGo 12.0 after four hours?

No, you should not remove the patch if the prescribed treatment is the labeled IontoGo 12.0 treatment.

The 12.0 IFU specifically directs the clinician to instruct the patient to remove the patch after 12 hours. The patch is designed around an approximately 12-hour delivery period. Removing it after four hours should not be assumed to provide the full labeled 80 mA-min treatment.

Likewise, IontoGo 4.0 should not be converted into a 12-hour patch simply by leaving it attached longer. Its IFU directs removal after approximately four hours.

The 4.0 and 12.0 are separate device models, not one patch with an optional wear-time setting.

Does SHUNT mean the patch can stay on indefinitely?

No.

IontoGo 4.0 and 12.0 use ACTIVApatch's SHUNT® treatment-termination technology, but the current instructions still specify removal at the model's designated time. Balego has a separate SHUNT Technology Guide explaining why electrical treatment completion and physical patch-removal time are separate considerations.

Keeping the patch attached beyond its instructed wear period should not be presented as beneficial simply because the electrical treatment has ended.

An important medication-polarity correction

The current model-specific Instructions for Use for both IontoGo 4.0 and IontoGo 12.0 state that the products should be used only with negatively charged solutions.

That is important because older or generic discussions of iontophoresis often describe both positive and negative drug electrodes.

Those general polarity rules remain relevant to iontophoresis as a modality, but they do not override the labeling of a particular patch.

For IontoGo:

For broader medication evidence and polarity information, use our Iontophoresis Medications & Substances Guide. That resource reviews medication polarity separately from the labeling of any one delivery device.

Does IontoGo 4.0 offer a 40 mA-min setting?

The current IontoGo 4.0 IFU specifies an 80 mA-min treatment over approximately four hours. It does not present 40 mA-min as a selectable IontoGo 4.0 treatment.

The ACTIVApatch product that currently offers both 40 and 80 mA-min treatment options is IntelliDose 2.5.

We explain that model's microprocessor and SmartPower™ status system separately in the IntelliDose 2.5 LED Guide, so those features do not need to be repeated in this 4.0-vs.-12.0 comparison.

Do the two IontoGo models have different medication solution capacities?

No.

The specifications list a 2.0 cc reservoir fill volume for both IontoGo 4.0 and 12.0. Both also list an active area of 11.4 cm².

The 12-hour treatment, therefore, should not be described as having a larger reservoir, a larger active electrode, or “more medication capacity” than the 4-hour treatment.

Choosing based on the treatment site

The treatment site's movement during the wear period matters.

Both IFUs state that the patches can be worn during normal activity, but excessive movement around the application area may cause poor skin-electrode contact. Poor contact can result in uneven current distribution and greater irritation risk.

A useful pre-application question is therefore not simply

“Can the patient tolerate a 12-hour treatment?”

It is:

“Can this particular patch remain properly positioned and adhered at this particular treatment site for the entire prescribed wear period?”

A four-hour window may be easier to accommodate in a highly mobile body region or during an active schedule. A 12-hour window may work well when the site and schedule permit reliable extended contact. That is a workflow consideration rather than a diagnosis-specific treatment recommendation.

IontoGo 4.0 vs. 12.0 decision table

What both IontoGo models have in common

The 4.0-versus-12.0 decision should not let features that are actually the same distort it.

Both models are self-powered and self-contained. Neither requires a conventional clinic dose controller or external lead wires. Both use the ACTIVApatch no-saline hydrogel dispersive design, both have a 2.0 cc medication reservoir, and both are single-use products.

Both current IFUs also state that the patch itself is not made with natural rubber latex.

For a complete three-model comparison including IntelliDose 2.5, use the ACTIVApatch product page. The purpose of this article is specifically to answer the narrower 4-hour versus 12-hour IontoGo decision without duplicating that broader product guide.

Important similarities in the Instructions for Use

Both models carry similar application and safety requirements.

The current IFUs require intact skin, instruct users not to apply the product to damaged skin or recent scar tissue, warn about irritation and burns, prohibit use during MRI, direct removal for burning or discomfort, and caution against metal or jewelry contacting the electrodes. They also list cardiac pacemakers or other electrically sensitive implanted devices, sensitivity to the ionic solution, and known adverse reactions to electrical current among their contraindications.

Both devices are also labeled as prescription devices under U.S. federal law.

Those requirements apply regardless of whether the four- or 12-hour model is selected.

Frequently asked questions

What is the main difference between IontoGo 4.0 and IontoGo 12.0?

Treatment time and delivery profile. Both are labeled for an 80 mA-min electrical treatment, but IontoGo 4.0 delivers it over approximately four hours and IontoGo 12.0 over approximately 12 hours.

Is the IontoGo 12.0 dose larger?

No. Both models have a labeled electrical dose of 80 mA-min.

Does IontoGo 4.0 offer 40 and 80 mA-min settings?

Not according to the current model-specific IFU. IontoGo 4.0 is described as an 80 mA-min device. The ACTIVApatch model that offers 40 or 80 mA-min options is IntelliDose 2.5.

Is IontoGo 12.0 automatically better for sensitive skin?

No. The labeling does not establish it as the universal sensitive-skin choice. Both models use hypoallergenic adhesive, and both warn that iontophoresis can cause skin irritation or burns.

Can I take the 12-hour patch off after four hours?

The IontoGo 12.0 IFU directs removal after 12 hours. Removing it substantially earlier should not be assumed to provide its complete labeled electrical treatment.

Can I leave IontoGo 4.0 attached for 12 hours?

No. The current IontoGo 4.0 instructions direct the clinician to tell the patient to remove it after four hours.

Do the two models have different reservoir sizes?

No. Both current pages list a 2.0 cc reservoir and 11.4 cm² active area.

Do IontoGo patches require saline?

No. The current IontoGo design uses hydrogel dispersive technology that does not require separate saline preparation.

Can I use positively charged medication with IontoGo?

Current model-specific IontoGo 4.0 and 12.0 IFUs state to use only negatively charged solutions. Medication selection and formulation should follow the prescription, pharmacy guidance, and device IFU.

Do the patches contain medication?

No. The medication solution is supplied separately according to the prescription; the IFUs direct the clinician to load 2.0 cc into the active reservoir.

How many IontoGo patches come in a box?

IontoGo 4.0 and IontoGo 12.0 are supplied in six-treatment boxes. The specifications list six patches together with alcohol wipes.

Where can I buy both versions?

We offer both models together on the ACTIVApatch Iontophoresis Patches product page, along with IntelliDose 2.5.

Bottom line

Choose IontoGo 4.0 and IontoGo 12.0 by the prescribed delivery profile—not by assuming one contains more medication or is inherently more effective.

Both current IontoGo models are 80 mA-min, 2.0 cc, negative-polarity iontophoresis systems with the same listed active area. The defining difference is that one is designed around approximately four hours of treatment and the other approximately 12 hours.

The clinician should choose the appropriate device based on the prescription, medication compatibility, treatment site, skin status, ability to maintain reliable patch contact, and required wear schedule.

For the electrical dose and automatic-completion mechanism, read How ACTIVApatch SHUNT Technology Works. For medication polarity and published drug literature, use Balego's Iontophoresis Medications & Substances Guide. To compare or purchase the current patches, see ACTIVApatch IontoGo 4.0, IontoGo 12.0 & IntelliDose 2.5.

Professional-use notice: Current IontoGo labeling restricts these devices to prescription use. Medication, formulation, treatment site, patch model, and treatment schedule should follow the prescription and current manufacturer instructions for use. Both IontoGo IFUs warn that improper iontophoresis use can produce skin irritation or burns.